- Home
- DC vs ALLO Comparison
DC vs ALLO Comparison
Compare DC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DC | ALLO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.0M | 707.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DC | ALLO |
|---|---|---|
| Price | $4.29 | $2.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $9.48 | $8.35 |
| AVG Volume (30 Days) | 2.0M | ★ 8.7M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $0.99 |
| 52 Week High | $7.25 | $4.46 |
Technical Indicators
Market Signals| Indicator | DC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 60.30 |
| Support Level | $3.85 | $2.12 |
| Resistance Level | $4.43 | $2.36 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 15.03 | 92.86 |
Price Performance
Historical ComparisonAbout DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).